Announcements Trials
Browse Landscape

Status

Available 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 4Expanded_access 2

Sponsor

Cancer Type

Tumor-Agnostic 1Genitourinary 1

Conditions

Prostatic Neoplasms 1Neoplasm Metastasis 1

Interventions

3-Iodobenzylguanidine 9Amifampridine 6nilotinib 5Magnetic Resonance Spectroscopy 5Cyclophosphamide 5trametinib 4pembrolizumab 4gallium 68 PSMA-11 4fludarabine 4elotuzumab 4dabrafenib 4Nivolumab 4Bortezomib 4Afatinib 4venetoclax 3regorafenib 3midostaurin 3fludarabine phosphate 3TIC10 compound 3Sunitinib 3Prednisone 3Lenalidomide 3Ipilimumab 3Everolimus 3Dexamethasone 3Crizotinib 3Capecitabine 3Axitinib 3Alpelisib 3Abiraterone Acetate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Expanded_access × tempol × Clear all
NCT05491928 2022-09-01

Treatment of Metastatic Cancer in Terminally Diagnosed Patients

Matrix Biomed, Inc.

Available
Tumor-Agnostic

Neoplasm Metastasis

NCT04337099 2021-05-05

A Single Patient Compassionate Use of MBM-02 (Tempol) for the Treatment of Prostate Cancer

Matrix Biomed, Inc.

Available
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡